Researchers at Jinan University (Guangdong) and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have synthesized...

Hangzhou Glubio Therapeutics Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase protein binding moieties covalently linked to Wee1-like protein kinase (Wee1) binding moieties.

Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has divulged aromatic heterocyclic compounds acting as lysine-specific histone demethylase 1A (KDM1A; LSD1) inhibitors reported to be useful for the treatment of cancer.

Insilico Medicine IP Ltd. has identified small-molecule inhibitors of ubiquitin carboxyl-terminal hydrolase 1 (USP1) reported to be useful for the treatment of cancer.

Vigil Neuroscience Inc. has synthesized heterocyclic compounds acting as triggering...

Umecrine AB has disclosed GABA-A receptor antagonists reported to be useful for the...

BioWorld MedTech presents Patent Highlights, an excerpt of the most important med-tech patents from this week's Cortellis Patents Gazette.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. researchers have identified mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.

AC Immune SA has patented 4h-imidazo[1,5-b]pyrazole derivatives and labeled compounds targeting α-synuclein (SNCA). They are reported to be useful for diagnosis of multiple system atrophy, Parkinson’s dementia, Lewy body dementia, Alzheimer’s and Parkinson’s disease, among others.

Cerevance Inc. has described N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives acting as ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors. As such, they are reported to be useful for the treatment of aging, diabetic nephropathy, glaucoma, inflammatory disorders, metabolic syndrome, obesity and rheumatoid arthritis.